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Abstract
Background: To date, clinical trials have reported inconsistent results on the efficacy
of the combination therapy of Memantine plus an acetylcholinesterase inhibitor
(AChEI) over a single-drug therapy in the treatment of Alzheimer’s disease. This
meta-analysis aim is to assess the efficacy of the combination therapy of Memantine
plus an AChEI in the treatment of Alzheimer’s disease compared with a single-drug
therapy using an AChEI.
Methods: PubMed, Embase, and Cochrane library databases were searched through
December 2013. Seven randomized controlled trials were included in the meta-
analysis. A random-effects meta-analysis was used. Heterogeneity and publication
bias were assessed.
Results: A  combination  therapy  of  an  AChEI  with  memantine  was  associated  with
modestly better effects in terms of cognition and global function compared to a
monotherapy with an AChEI. The effects of the combination therapy were no better
than a monotherapy for daily living activity. However, the combination therapy
showed benefits over a monotherapy for the behavioral outcome and the effect was
independent of the stage of the disease. Moreover, the rate of adverse effects did not
differ between a combination therapy and a single therapy.
3Conclusions: The findings of this meta-analysis suggest that the combination therapy
is more appropriate and should be administered for patients in more advanced stages.
However, not all patients may benefit from the combination treatment. Identification
of  subgroups  of  patients  with  Alzheimer’s  disease  who  will  benefit  more  from  the
combination treatment is needed.
Key words: Acetylcholinesterase inhibitor, Alzheimer’s disease, donepezil,
galantamine, memantine, rivastigmine, meta-analysis.
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71 Introduction
The population ageing is a global phenomenon. Estimates show that in 2050 the world
population over the age of 60 will be 2 billion and the proportion of old people will be
increasing constantly (United Nations [UN], 2009). The occurrence of dementia is
strongly related to population ageing (Qiu, Kivipelto, & von Strauss, 2009). The
developing countries are facing a greater challenge as their huge increase in
population entails a rise in the number of aged people and as a consequence a rise in
the number of people affected by dementia (UN, 2009).
The term ‘dementia’ describes the clinical syndrome characterized by cluster of
symptoms and their progressive worsening which is manifested by difficulties in
remembering and gradual loss of memory, mood and behavioural changes, speech
impediment and other cognitive functions, such as communication problems, thinking
and reasoning problems, and reduction in capability and ultimately inability to
perform daily activities (World Health Organization [WHO], 2012).
According to the World Health Organization and Alzheimer’s Disease International
report, the total number of people with dementia worldwide in 2010 was estimated to
be 35.6 million and that figure is expected to double nearly every 20 years to 65.7
million by 2030 and 115.4 million by 2050.  The cost of dementia globally in 2010
was $604bn (£381bn; €462bn) (Alzheimer's Disease International, 2010). The report
informs that  dementia  is  a  global  problem and  suggests  that  all  governments  should
take action towards dementia in their national health policies, focused on the key
message: “Dementia is not a normal part of ageing” (Alzheimer's Disease
International, 2010).
Alzheimer’s disease is the most common type of dementia accounting for 50-70% of
all dementia cases and maintaining the same proportions in all populations of the
globe. The disease was described a century ago by the German psychiatrist Alois
Alzheimer and was named after him, in his honor (Ferri et al., 2005; Qiu et al., 2009;
Reitz, Brayne, & Mayeux, 2011) .
82 Rationale of this review
The economic impact of Alzheimer’s disease and the lack of new more effective
drugs, has turned the focus of the investigation on a better treatment with the current
available and widely prescribed drugs aiming at reducing the deterioration caused by
the disease and hindering its development.
Thus, the current research is focussing on the investigation of the combination of an
acetylcholinesterase inhibitor (AChEI) and memantine, which are drugs that have
complementary action and are the most commonly used for the treatment of
Alzheimer’s patients. The combination therapy may be more beneficial than a
monotherapy with either one of these drugs.
To date, clinical trials and reviews have reported inconsistent results on the efficacy
of the combination therapy over the monotherapy. Some clinical trials among
moderate-to-severe patients found some benefits in the combination therapy
(Grossberg et al., 2013; Howard et al., 2012; Tariot et al., 2004) ,but no benefits for
mild-to-moderate patients (Choi et al., 2011; Farlow, Alva, Meng, & Olin, 2010;
Porsteinsson, Grossberg, Mintzer, Olin, & Memantine MEM-MD-12 Study Group,
2008). In addition, a review (Farlow & Cummings, 2007) of published trials found no
evidence of the effectiveness of the combination therapy over the monotherapy for the
earlier stages of Alzheimer’s disease. Other reviews found some evidence in support
of using the combination therapy over the monotherapy for moderate stage (Farlow &
Cummings, 2007) and moderate-to-severe stage (Tampi & van Dyck, 2007).
Moreover, some other reviews suggested that the combination therapy is the most
effective for the treatment of all stages of Alzheimer’s disease (Grossberg, Edwards,
& Zhao, 2006; Standridge, 2004) .
A thorough investigation in the contents of the reviews showed that the variability of
their outcomes is dependent on the period they were conducted, on the studies they
included, on the approach they used (narrative or systematic) and on the outcome
measures (i.e. different measurement scales). As the outcomes of the reviews are
shaping opinions of the decision makers for the approval of a drug to be prescribed by
9the national health systems, the issue of cost-effectiveness is involved with the
efficacy of a drug. The research findings showed that although a combination therapy
increases the treatment costs, it decreases total lifetime Alzheimer’s disease-related
care costs (Weycker et al., 2007).
Hence, there is a need for further examination on the efficacy of the combination
therapy of an AChEI together with memantine for Alzheimer’s patients, through an
updated review which may provide a better insight in the matter.
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3  Objectives
Overall objective
The aim of  this  systematic  review and  meta-analysis  was  to  assess  the  efficacy  of  a
combination  therapy  of  Memantine  plus  an  AChEI  in  the  treatment  of  Alzheimer’s
disease compared to a single-drug therapy using an AChEI.
Specific objectives
· To assess the effects of the combination therapy of memantine plus an AChEI
on the declination of Alzheimer’s patients in terms of cognitive function,
activities of daily living and global function compared to treatment of with
only an AChEI.
· To assess the safety and tolerability of the combination therapy of memantine
plus an AChEI compared to an AChEI monotherapy.
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4  Review of literature
4.1 Dementia and Alzheimer’s disease
Dementia  is  a  uniform  term,  which  comprises  many  different  types  of  that
syndrome. The most common types are: Alzheimer’s disease, vascular dementia,
dementia with Lewy bodies, fronto-temporal dementia, mild cognitive impairment,
Creutzfeldt-Jakob disease, Korsakoff’s syndrome. Diseases which affect the
neuronal system such as multiple sclerosis, motor neurone disease, Parkinson’s
disease and Huntington’s disease incorporate increased risk of dementia without
constituting dementia type themselves (Lakey, Chandaria, Quince, Kane, &
Saunders, 2012). Interestingly, some types of dementia are far more common than
others and especially Alzheimer’s disease is keeping dominant position among all
(Lakey et al., 2012).
The Alzheimer’s type dementia is a progressive neurodegenerative disorder
characterized by the presence of excess neuritic extracellular amyloid plaques – which
are usually surrounded by dystrophic neurites – and intracellular neurofibrillary
tangles in the cerebral cortex (Cummings & Cole, 2002; Reitz et al., 2011) .
There is increasing evidence that the pathology of Alzheimer’s starts decades before
the onset of the clinical symptoms and many biomarkers are associated with it.
Furthermore, it is supported that once the symptoms of dementia appear, significant
neuronal loss has already occurred and the disease progression is inevitable (Sperling
et al., 2011).
Currently there is no cure for Alzheimer’s at any stage of the disease. Recent research
suggests that treatments should intervene during the symptomatic period of the
neurologic damage rather than later at the onset of symptomatic dementia (Sperling et
al., 2011).
Estimations show that there were over 35 million people with dementia worldwide in
2010.  This number is anticipated to nearly double every 20 years, to reach to 65.7
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million in 2030, and 115.4 million in 2050 (Alzheimer’s Disease International, 2011).
Currently 58% of people with dementia live in developing countries, but by 2050 this
number is expected to rise up to 71%. The numbers in developed countries are
expected to increase by 100% between 2001 and 2040. Particularly, the fastest growth
is taking place in India, China, and their south Asian and western Pacific neighbours
where the increase in number of cases is anticipated to exceed 300% (Ferri et al.,
2005).  In USA one in eight older Americans has Alzheimer’s,  putting the disease in
the position of the sixth leading cause of death in USA. The healthcare payments for
the  disease  in  USA alone  in  2012 were  over  200$ billion  (Alzheimer’s  Association,
2012).
The international literature shows increasing incidence of the disease and its
confrontation is putting it in the forefront of research globally. The international
research focuses its aims either on treatment and improvement of cognition and
quality of life of patients, or on the discovery of the disease’s aetiology and therefore
its  prevention.   As  regards  the  first,  the  research  efforts  are  focusing  on  the
development a new generation of more effective treatments using the most updated
findings of medicine and biology. As for the second, the efforts are focusing on all the
biological, social, economic and environmental factors that may support a healthy
ageing.
4.2 The pathophysiology of Alzheimer's disease
Alzheimer’s disease is a progressive brain disorder that damages and eventually
destroys brain cells, leading to loss of memory, thinking and other brain functions.
Alzheimer's disease is not a part of normal aging, but results from a complex pattern
of  abnormal  changes.  It  usually  develops  slowly  and  gradually  gets  worse  as  more
brain cells wither and die. Ultimately, Alzheimer's disease is fatal, and currently, there
is no cure (Cummings & Cole, 2002).
The pathophysiology lying behind the Alzheimer’s disease symptoms is characterized
by two microscopic neuropathological hallmarks: the extracellular amyloid plaques
and intracellular neurofibrillary tangles (Waldemar & Burns, 2009). The amyloid
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plaques’ compound is mainly the neurotoxic peptide amyloid (Aβ, Abeta) which is
cleaved sequentially from a larger amyloid precursor protein (APP) by two enzymes:
β-secretase and γ-secretase (comprising four proteins, one of which is presenilin).
Hence, Aβ will not be formed if APP will be cleaved at first by the enzyme α-
secretase and not β-secretase (Waldemar & Burns, 2009). Neurofibrillary tangles’
compound is mainly the protein tau which binds microtubules and thus facilitates the
neuronal transport system. The uncoupling of tau from microtubules and furthermore
their aggregation into tangles inhibits transport and has as a consequence the
microtubule’s disassembly. The phosphorylation of tau may play an important role in
this process too (Waldemar & Burns, 2009).
Interestingly, some aspects of Alzheimer’s disease pathology are found also in normal
ageing, but the increasing density of the neuritic plaques and neurofibrillary tangles
that are consequent of the Alzheimer’s disease  progress can be distinguished from
those of normal aged people (Cummings & Cole, 2002; Parsons, Danysz, Dekundy, &
Pulte, 2013).
Alzheimer’s disease was initially thought to be solely a result of a cholinergic deficit.
Although the primary focus has been on the cholinergic system, other
neurotransmitters, including dopamine, noradrenalin, serotonin, and glutamate, have
been shown to reduce or dysregulate when the disease occurs (Geerts & Grossberg,
2006). The involvement of these neurotransmitters (dopamine, noradrenaline,
serotonine and glutamate) during the development of the disease and the interactive
regulation of these transmitter actions led to conclusions that the neurotransmitter
systems that mostly need to be studied for the pathogenesis of Alzheimer’s disease
are both the cholinergic and glutamatergic systems (Hynd, Scott, & Dodd, 2004;
Terry & Buccafusco, 2003). Thus, the evidence for the rationale of the
pharmacological treatment of Alzheimer’s disease with AChEIs and memantine is
based on the concept of the selective vulnerability of neuronal systems such as the
cholinergic, serotonergic, noradrenergic and glutamatergic (Geerts & Grossberg,
2006).
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4.3 Prevalence
In 2003, Wimo et al., stated that the population affected by dementia around the world
in 2000 was 25 million people and estimated that the future trend of dementia
increasing to 63 million cases by 2030 and 114 million by 2050 (Wimo, Winblad,
AgueroTorres, & von Strauss, 2003). Two years later a group of experts assigned by
the Alzheimer’s Disease International, reviewed the available epidemiological data
and reported similar estimations: a current number of 24.3 million of dementia cases
in ages above 60+ years old, which increases with 4.6 million new cases every year,
will double every 20 years, rising finally to 81.1 million by 2040 (Ferri et al., 2005).
Moreover, it was stated that most people with dementia 60+ years old, live in
developing countries. Indeed, China and developing western Pacific countries have
the highest number of people with dementia (6 million), but not the highest
prevalence (4.0%). The European Union follows with 5.0 million people with
dementia, but remarkably higher prevalence (5.4%) and then USA with 2.9 million
people with dementia and the highest prevalence among the world regions (6.4%).
Interestingly, there were 1.5 million of dementia cases in India and the prevalence was
1.9%. There is a variation in the rates of dementia cases across the world; the numbers
in developed countries are going to increase by 100% between 2001 and 2040,
whereas in India, China, and other south Asian and western Pacific countries the
increase will be more than 300% (Ferri et al., 2005).
Four population-based studies with different inclusion criteria, reported age-specific
prevalence of dementia and Alzheimer’s disease across four regions (Table 1):
Europe, USA, China and Brazil. The European study among people over 65 years of
age  showed  prevalence  of  6.4  %  for  dementia  and  4.4  %  for  Alzheimer’s  disease
(Lobo et al., 2000). The US national representative sample study of individuals over
70 years old yielded prevalence of 9.7 % for Alzheimer’s disease (Plassman et al.,
2007) while the prevalence for all types of dementia was 13.9%. In China, two
different meta-analyses stated that the pooled prevalence of Alzheimer’s disease for
the population over 60 years old was between 1.6% and 1.9% and the prevalence of
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dementia was  between 3.0 and 3.2%, rising the current prevalence rate of dementia in
China closer to that of the developed countries (Dong et al., 2007; Zhang et al., 2012).
The Brazilian study of a community of individuals with low socioeconomic status
stated that the prevalence of dementia among individuals over 65 years old was 5.1%
and the Alzheimer’s prevalence in this population was 1.6% (Scazufca et al., 2008).
Table 1. Prevalence (%) of dementia and Alzheimer’s disease by country
Country Age range Dementia Alzheimer’s
disease
Reference
E.U. 65+ 6.4 4.4 (Lobo et al., 2000)
U.S.A 70+ 13.9 9.7 (Plassman et al., 2007)
China 60+ 3.0-3.2 1.6-1.9 (Dong et al., 2007;
Zhang et al., 2012)
Brazil 65+ 5.1 1.6 (Scazufca et al., 2008)
Cuba 65+ 6.4 Not reported (Llibre Rodriguez et
al., 2008)
Egypt 65+ 4.5 2.2 (Farrag, Farwiz,
Khedr, Mahfouz, &
Omran, 1998)
Israel (Arabs-
S. Haifa)
60+ Not reported 20.5 (Bowirrat, Treves,
Friedland, & Korczyn,
2001)
Similarly,  a survey of urban populations in the cities Havana and Matanzas of Cuba
has reported the prevalence of 6.4% for dementia, according to DSM-IV criteria
(American Psychiatric Association, 2000), for persons over 65 years old (Llibre
Rodriguez et al., 2008) and a study of the Upper Assiut region population in Egypt
reported the dementia prevalence of 4.5% and Alzheimer’s prevalence 2.2% in
persons over 65 years old (Farrag et al., 1998). Beyond the similar rates of various
epidemiological  studies  from  different  parts  of  the  world,  the  study  of  the  Arab
population of south of Haifa in Israel, yielded crude prevalence estimate for
Alzheimer’s disease at  20.5%  among the individuals over 60 years old (Bowirrat  et
al.,  2001).  This exceptional outcome was explained by the authors as a result  of the
consanguinity among families of this community (Farrer et al., 2003) (Table 1).
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However,  even  though the  rates  of  prevalence  seem to  converge  roughly  all  around
the world, favouring the developing countries, the numbers of dementia and
Alzheimer’s cases seem to increase tremendously in the developing countries due to
their populations sizes.
In  addition,  over  viewing  in  the  pattern  of  dementia  subtypes  across  the  world  the
proportion of Alzheimer’s disease cases among the demented populations remain
constant and accounting for 50-70% of all dementia cases, placing Alzheimer’s in the
position most common form of dementia (Ferri et al., 2005; Qiu et al., 2009).
4.4 Incidence
The global annual incidence of dementia is around 7.5 per 1,000 persons (Ferri et al.,
2005). The incidence rate of dementia increases exponentially with age, from
approximately one per 1,000 person-years in people aged 60-64 to more than 70 per
1,000 person-years in the ages above 90 year old. The incidence rates of dementia
across several regions are similar among the younger ages (under 75 years), but
greater variations are seen in individuals aged above 70 years old (Qiu, De Ronchi, &
Fratiglioni, 2007).
The pooled data from eight European population studies from seven different
countries (Finland, Sweden, Netherlands, Denmark, United Kingdom, France, Spain)
showed that the incidence rate of Alzheimer’s disease among people over 65 years old
in  Europe  was  19.4  per  1000  person-years.  In  addition,  there  has  been  some
geographic variations in the incidence; being higher among the very old people of
north-western countries compared with those of southern countries.
The incidence of dementia and Alzheimer’s also differed according to age group and
gender, rising in the very old ages (over 85 years old), but only among women and not
among men (Fratiglioni et al., 2000). However, the Cache County Study found that
the incidence of Alzheimer’s disease increased with age, peaked, and then started to
decline  at  extreme old  ages  (over  85  years)  for  both  men and  women (Miech  et  al.,
2002).
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 Two US large-scale community based studies of persons aged over 65 years old
reported an Alzheimer’s disease incidence of 15.0 per 1,000 person-years with the
sex-specific incidence rates for males and females being 13.0 and 16.9 per 1,000
person-years, respectively (Kawas, Gray, Brookmeyer, Fozard, & Zonderman, 2000;
Kukull et al., 2002).
A 3-year follow-up Swedish study involving 987 persons aged 75 years or older found
the incidence rate of dementia in the age group of 75-79 years to be 19.6 and 12.4 per
1,000 person-years for women and men, respectively; whereas for the age group
above 90 the rates were 86.7 and 15.0 per 1,000 person-years respectively (Fratiglioni
et al., 1997).
A 3-year follow-up British study of persons aged 65 or older showed the incidence of
all  types  of  dementia  9.2  per  1,000  person-years,  of  which  the  Alzheimer’s  disease
incidence was 6.3 per 1,000 person-years (Copeland et al., 1992). Another British
population multisite study which aimed to measure the variation of incidence of
dementia and Alzheimer’s disease across five regions within England and Wales
found neither evidence of variation in dementia incidence among these regions, nor
slowing of the incidence in the oldest age groups (Matthews, Brayne, & Medical
Research Council Cognitive Function and Ageing Study Investigators, 2005).
A recent recent epidemiological study on Alzheimer’s disease incidence reported that
the incidence increases exponentially with increasing age (Xu, Ferrari & Wang,
2013). Moreover, the incidence of Alzheimer’s disease at age 80 was higher in North
America (20.6 / 1 000 person years) and Europe (15.1) than in the other countries
(8.3).  It  is  noteworthy that this systematic review outcome emerged from 20 studies
coming  from  North  America  and  Europe  and  only  7  studies  that  came  from  other
countries (3 from Japan, 1 from China (province of Taiwan), 1 from India, 1 from
Nigeria and 1 from Brazil (Ziegler-Graham, Brookmeyer, Johnson, & Arrighi, 2008).
Studies  of  populations  from  other  than  North  America  and  EU  countries  also
demonstrate lower Alzheimer’s disease incidence. As an example, the incidence rate
in a rural Indian population was estimated at 3.2 per 1000 person-years (Chandra et
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al., 2001); in a Brazilian population aged above 65 was estimated at 7.7 per 1000
person-years (Nitrini et al., 2004); and in a Japanese community it was 5.1 and 10.9
per 1000 person-years for men and women respectively (Yoshitake et al., 1995).
In conclusion, an exponential increase in Alzheimer’s disease’s incidence rate may be
related to the age increase in many of the above mentioned populations. This might be
an indication that Alzheimer’s disease is a consequence of ageing, but interestingly a
configuration of a restrain of this upward trend for persons aged above 85 years old
may indicate a reduction of the vulnerability in very old people due to genetic or
environmental  factors  or  might  be  simply  affected  by  the  survival  effect  in  this  old
age groups (Miech et al., 2002).  However, the distribution by age and gender which
may be observed in the rates of Alzheimer’s disease, shows that females have
increased risk in developing the disease and it is consistent with the findings coming
up from the incidence data of the Kungsholmen Project which show that women have
approximately 3-fold higher risk of developing the disease (Fratiglioni et al., 1997).
4.5 The burden of the disease
Dementia and Alzheimer’s disease have a complex impact on individual and
socioeconomic level. Dementia is the major determinant of developing dependence
and functional decline. A follow-up study showed that about half of the persons who
developed functional dependence had a type of dementia (Aguero-Torres et al., 1998).
Reports from WHO (World Health Organization) and Alzheimer’s Association
underline that Alzheimer’s disease is one of the major causes of disability in later life
globally, without discrimination between the developed and developing countries
(Alzheimer's Disease International, 2010; WHO 2008).
The average survival period after the diagnosis of the Alzheimer’s disease is
approximately 4-8 years for people over 65 years old, while some patients may live
till 20 years after the first diagnosis (Alzheimer’s Association, 2013; Arrighi,
Neumann, Lieberburg, & Townsend, 2010). Of all these years, on an average, an
Alzheimer’s patient will spend more years in the most severe stage. Especially, for the
patients in the ages between 70 and 80 years, the typical development of the disease
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according the Clinical Dementia Rating (CDR) of Hughes, Berg, Danziger, Coben, &
Martin (1982), is 3 years in stage 1 (mild), 3 years in stage 2 (moderate) and 4 years
in stage 3 (severe) (Arrighi et al., 2010).
Similarly, estimates from a US population show that 40% of the total number of years
with the disease is spent in a nursing home (Alzheimer’s Association, 2013), and
while the deaths from all causes are 30% by the age of 80 years, the percentage for the
Alzheimer’s disease patients increases to 61% (Arrighi et  al.,  2010).  Also,  when the
admission to nursing home for the general population of 80 years old is only 4%, for
the Alzheimer’s disease patients surviving in this age is 75% (Arrighi et al., 2010).
Thus, the long duration of the disease before death increases significantly the
economic impact of the disease.
The demands for healthcare and social service for the huge and rapidly growing
numbers of dementia patients have a major economic impact on the societal level
(Alzheimer’s Association, 2013; WHO 2008). Surprisingly, the direct medical care
costs contribute to 16% of the total costs of the disease, and particularly in the low-
income countries, most costs derive from unpaid care provided by family members
and others (Alzheimer's Disease International, 2010). Nonetheless, the developing
countries are expected to carry the bigger burden of the disease in the future, as the
last decade’s (2010) estimate shows that 58% of the total people with dementia live in
these countries and anticipate that this number in 2050 will rise to 71% (Kinsella &
Velkoff, 2002). Dementia costs in developing countries are estimated to be US$73
billion yearly, but the health care needs of the disease require social protection, which
seems scarce in these regions (Lakey et al., 2012).
In the World Alzheimer Report 2010 it is commented: “The total estimated worldwide
costs of dementia in 2010 were US$604 billion. These costs account for around 1% of
the world’s gross domestic product, varying from 0.24% in low income countries, to
0.35% in low-middle income countries, 0.50% in high-middle income countries, and
1.24%  in  high  income  countries.  If  dementia  care  were  a  country,  it  would  be  the
world’s 18th largest economy, ranking between Turkey and Indonesia. If it were a
company, it would be the world’s largest by annual revenue exceeding Wal-Mart
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(US$414 billion) and Exxon Mobil (US$311 billion)” (Alzheimer's Disease
International, 2010).
In the above mentioned total costs are also included - except from the direct costs
related to medical, hospital and social care - the family care costs (informal costs)
which are not negligible, given that they count approximately 41% of the total costs.
As, usually a person with Alzheimer’s disease occupies family caregivers with unpaid
care status and the burden for these caregivers is high in terms of man-hours occupied
into activities related directly or indirectly to the patient. In addition, the caregivers
undergo an important psychological burden related to the continuous care and dealing
with a person with dementia,  as a “full  time job” with no breaks for week-ends and
holidays (WHO, Alzheimer's Disease International, 2012). As a result, caregivers of
Alzheimer’s patients show all the features of a chronic stress experience with all the
consequent health effects (Schulz & Sherwood, 2008).
In conclusion, while the numbers of persons with Alzheimer’s disease are increasing
exponentially, the burden of the disease is becoming devastating too. Simultaneously,
the disease has an indirect socioeconomic impact, not only on those who have the
disorder (i.e. stigmatism, ethical issues), but also on their caregivers and their families
which cannot be disregarded (WHO, 2012).  Hence, the confrontation or
postponement  of  the  onset  of  the  disease  and  the  application  of  the  most  effective
treatment when the disease occurs is manifested as a global challenge.
4.6 Determinants of Alzheimer’s disease
An overview of epidemiological studies, genetic studies, neuroimaging methods and
neuropathology research, used to explain the development of Alzheimer’s disease.
The conclusions converge that it is a multi-aetiology degenerative, incurable and fatal
disorder. Its basic etiological risk factors could be resumed in four major categories:
biological, genetic, vascular and psychosocial (Povova et al., 2012). Furthermore,
other factors such as nutrition, exposure to various substances and inflammation are
suspended to play a role for the occurrence of the disease, but with insufficient level
of evidence (Povova et al., 2012).
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4.6.1 Biological risk factors
4.6.1.1 Ageing
Alzheimer’s disease is characterized as an ageing phenomenon. Indeed, increasing
age is the most well-established risk factor for Alzheimer’s disease, as the incidence
of the disease almost doubles with every 5 years of age (Fratiglioni & Rocca, 2001).
The strong association of Alzheimer’s disease with the increasing age may also be
explained as the cumulative effect of different risk and protective factors and their
complex interactions over the lifespan (Xu et al., 2013). Indeed, most cases of
Alzheimer’s disease are developed after the age of 60 years. That type of disease is
called late-onset Alzheimer’s. However, less than 5% of the cases occur in people in
ages between 30 and 60. That is called early-onset Alzheimer’s and is known also as
familial type Alzheimer’s. Estimates show that Alzheimer’s disease is the most
common dementia diagnosis among the cases with early-onset dementia. The
prevalence of early onset of dementia among the general population increases as the
age increases (Vieira et al., 2013).
4.6.1.2 Sex susceptibility
Alzheimer’s disease is gender related disease, as its prevalence is higher among
women than among men. Two follow-up studies found that women are at higher risk
of dementia and Alzheimer’s disease after the age of 80 than men, whereas men have
higher risk in ages younger than 80 years (Fratiglioni et al., 1997; Letenneur et al.,
1999). The findings of a recent study also support the hypothesis that sex is associated
with Alzheimer’s morbidity, as women appear to be at higher risk of disease,
especially in the older age (Qiu et al., 2007).
Almost two-thirds of Americans with Alzheimer’s disease are women (Qiu et al.,
2007). The explanation may be due to the fact that women live longer than men.
Women, therefore, are more likely to develop the disease, which is age-related
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condition (National Institute of Health [NIH], 2012). Moreover, women suffer from
more severe symptoms and experience faster declination than men do (NIH, 2012;
Roberts et al., 2012). They have higher prevalence of depression and anxiety, which
increase the risk of Alzheimer’s disease. Exercise protects against the disease and
women exercise less than men (NIH, 2012).  Finally, when spouses are caregivers for
diseased husbands with Alzheimer’s disease, they are experiencing high level of
chronic stress and depression, which is increasing the risk for Alzheimer’s disease. It
is clear that these health effects may be influenced by other cultural and
socioeconomic factors. Therefore, spouses with lower socioeconomic status may have
lower health performance, or they may have the same life-style and habits like their
husbands,  thus  they  are  exposed  to  the  same  risk  factors  for  Alzheimer’s  disease
(Schulz & Sherwood, 2008).
Last but not least, women health status is influenced by the changes that take place
during the menopausal transition which are closely linked to an increased risk of
cognitive decline and subsequent occurrence of dementia (Hathaway, 2012).
4.6.1.3 Racial Disparities
There are racial and ethnic differences in the causes, expression, and prevalence of
various diseases (Burchard et al., 2003). Burchard et al.  support that “the relative
importance of bias, culture, socioeconomic status, access to care, and environmental
and genetic influences on the development of disease is an empirical question that, in
most cases, remains unanswered” (Burchard et al., 2003).
Indeed, the apolipoprotein (APOE) ε4 allele which is a genetic factor with strong
association with Alzheimer’s disease occurrence has different frequency among
patients according to ethnicity and region (Farrer et al., 1997; Gerdes, Klausen, Sihm,
& Faergeman, 1992) . Although it exists in all racial and ethnic groups, it is met at
different frequencies, ranging from 9% in Japanese populations to 14% in white
populations to 19% in black American populations (Burchard et al., 2003); with the
highest frequencies met in Sudanese (29%) (Hallman et al., 1991), Dutch (30%) (Smit
et al., 1988), and in Finnish (23 - 24%) populations (Hallman et al., 1991).
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Interestingly, the expression of APOE ε4 allele varies according to the race and that
may conceal genetic or environmental modifiers of this gene (Burchard et al., 2003;
Farrer et al., 1997). Lindsay et al., in a systematic review, reported that the APOE ε4
allele frequency in Caucasians and African Americans with Alzheimer’s disease in the
USA reached 36.7% and 33.2%, respectively. These levels are higher than those of
Asiatic  Mongoloids  (Farrer  et  al.,  1997).  However,  the  findings  of  a  recent  study
which compared two Chinese populations of different race argued that the lack of
significant difference in APOE ε4 allele frequency may be due to the interactions of
protective environmental, nutritional and life lifestyle factors or due to a gradual
assimilation of these two populations (Del Parigi, Panza, Capurso, & Solfrizzi, 2006).
4.6.2 Genetic susceptibility and familial aggregation
Among the various etiological hypotheses for Alzheimer’s disease, the genetic
susceptibility hypothesis, which is related to APOE ε4 allele and the familial
aggregation, has the strongest level of supporting evidence. Therefore, the genetic
factors have the strongest causal relationship with the occurrence of Alzheimer’s
disease  (Qiu  et  al.,  2009).  The  APOE  ε4  allele  is  the  only  susceptibility  gene
correlated to both early- and late-onset Alzheimer’s disease. Increasing number of the
APOE  ε4  alleles,  increases  the  risk  of  the  disease,  although  this  gene  is  neither
necessary nor sufficient for the development of the disease. What is also interesting is
that the risk of the disease decreases as the age increases. This gene contributes to the
disease in 15% to 20% of cases only (Qiu, Kivipelto, AgueroTorres, Winblad, &
Fratiglioni, 2004).
The genetic susceptibility hypothesis is related to the phenomenon of familial
aggregation too, which manifests that the first-degree relatives of Alzheimer’s patients
have a higher lifetime risk of developing the disease than the general population or the
relatives of non-demented subjects (Qiu et al., 2009).  The familial aggregation causal
relationship is not involving only the presence of the APOE ε4 allele, but also other
genes susceptibility too (Huang, Qiu, von Strauss, Winblad, & Fratiglioni, 2004).
Especially, the early-onset Alzheimer’s disease is considered as the result of a
mutation in one of the three genes: APP (Amyloid Precursor protein), PS1 (presenilin
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1) or PS2 (presenilin 2) (Waldemar & Burns, 2009).  Additionally, the phenomenon
of familial aggregation may be attributed not only to genetic factors, but also to
common environmental or life-style factors, or both (Green et al., 2002).
4.6.3 Risk factors related to vascular hypothesis
The studies on incident cases of Alzheimer’s disease show that the disease is
associated with cigarette smoking, especially in APOE ε4 allele non-carriers. Besides,
research has found an interaction between smoking and the presence of the APOE ε4
allele  (Aggarwal  et  al.,  2006;  Launer  et  al.,  1999;  van  Duijn,  Havekes,  Van
Broeckhoven, de Knijff, & Hofman, 1995) .
Alcohol use causes alcohol dementia. Furthermore, middle-aged heavy drinkers who
are APOE ε4 allele carriers are 3-fold more likely to develop dementia and
Alzheimer’s disease. Heavy consumption of alcohol is associated with damages in the
brain, whereas moderate alcohol consumption is related to brain atrophy and volume
loss (Anttila et al., 2004).
Blood pressure and dementia are associated in a causal relationship more likely age-
dependent (Qiu et al., 2007). The midlife hypertension is linked to increased risk of
dementia and Alzheimer's disease, as hypertension is related either directly to the
neurodegenerative process itself or indirectly causing brain atrophy. Surprisingly, for
aged people low blood pressure is found to be predictive of dementia and Alzheimer’s
disease too (Qiu, von Strauss, Fastbom, Winblad, & Fratiglioni, 2003).
The ischemic heart disease and peripheral arterial disease are associated with
increased risk of developing Alzheimer’s disease (Newman et al., 2005). Other
cardiovascular diseases such as heart failure, atrial fibrillation, and severe
atherosclerosis are independently related to increased risk of Alzheimer’s disease (Qiu
et al., 2006). In addition, patients who have suffered from a stroke or clinically silent
cerebral infarction are at increased risk of Alzheimer’s disease (Honig et al., 2003;
Vermeer et al., 2003). Neuropathological studies suggest that cerebrovascular lesions,
atherosclerosis and neurodegenerative changes often coexist in the brain of
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Alzheimer’s patients (Esiri, Nagy, Smith, Barnetson, & Smith, 1999; Snowdon et al.,
1997) .
Persons with diabetes mellitus are facing an increased risk of developing Alzheimer’s
disease as their cognitive systems may be affected by the disease in various ways
(Arvanitakis, Wilson, Li, Aggarwal, & Bennett, 2006). Midlife diabetes or long
duration diabetes are considered to be a determinant of Alzheimer’s disease. The risk
is higher when diabetes occurs in mid-life than in late life (Xu et al., 2009). Moreover,
in very old people borderline or prediabetes or impaired glucose tolerance, are related
to higher risk of the disease (Xu, Qiu, Winblad, & Fratiglioni, 2007).
The elevated cholesterol in mid-life is associated with an increased risk of
Alzheimer’s disease in late-life. Decreasing cholesterol after midlife is also
considered as a biomarker of poorer cognitive status in late-life (Solomon et al., 2009;
Whitmer, Sidney, Selby, Johnston, & Yaffe, 2005). In addition, the statins, which are
cholesterol lowering drugs, may play a protective role on reducing β-amyloid
production, and therefore sustaining the central nervous system against the risk of
Alzheimer’s disease (Qiu et al., 2009).
The association between body mass index (BMI) and dementia is lifespan-dependent.
For middle-aged people a higher BMI is related to an increased risk of dementia in
late life (Gustafson et al., 2012; Xu et al., 2011). However, there is also an association
between an accelerated decline in BMI and the detection of Alzheimer’s disease,
approximately in the last 10 years before the onset of the disease (Johnson, Wilkins,
& Morris, 2006).
A number  of  studies  support  the  association  of  various  nutritional  elements  with  an
increased  risk  of  Alzheimer’s  disease  such  as:  (i)   Low  levels  of  B12  and  folate
(Wang et  al.,  2001) (ii)  Moderate intake of saturated fats (Morris et  al.,  2003),  even
more  for  APOE  ε4  allele  carriers  (Kivipelto  et  al.,  2008);  (iii)  fatty  acids  intake
through various mechanisms such as atherosclerosis and inflammation (Scarmeas,
Stern, Mayeux, & Luchsinger, 2006).
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4.6.4 Psychosocial and psychological factors
The epidemiological research provides evidence that these factors may play a role in
the onset andin the postponement of the disease and thereby affirms the opinion that
Alzheimer’s disease reflects the cumulative effect of different risk and protective
factors over the lifespan (Xu et al., 2013).
Social isolation, poor social network or social disengagement and unsatisfactory
contacts with relatives and friends in middle or late life are associated with an
increased risk of dementia and Alzheimer’s disease in older age (Bennett, Schneider,
Tang, Arnold, & Wilson, 2006; Fratiglioni, Wang, Ericsson, Maytan, & Winblad,
2000; Wang et al., 2009). In addition, history of major depression in a person’s life
span  may  be  a  risk  factor  for  later  development  of  Alzheimer’s  disease  and  the
depressive symptoms may facilitate the conversion of mild cognitive impairment to
Alzheimer’s disease. Research findings showed that the neuronal plaques and
neurofibrillary tangles which are the major hallmarks of Alzheimer’s patients’ brain
are more pronounced in the brains of those with comorbid depression than in those
without depression (Caraci, Copani, Nicoletti, & Drago, 2010).
4.6.5 Other factors
Lower education is linked to increased risk of dementia and Alzheimer’s disease. The
association between low education and dementia is probably not explained solely by
the unhealthy lifestyles of the less educated people (Karp et al., 2004), but also by the
fact that higher educated persons may have a greater cognitive reserve that can
postpone the clinical manifestation of the disease. The unhealthy lifestyles may
independently contribute to the depletion of this reserve or directly influence the
underlying pathologic processes (Ngandu et al., 2007). Interestingly, although both
education and socioeconomic status are strongly interconnected, well-educated
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subjects with low socioeconomic status were not found at high risk. Early life factors
may play a role in later health and cognitive status (Karp et al., 2004).
Recent studies have demonstrated a strong link between neurodegeneration and
chronic inflammation. Inflammations are involved in the atherosclerotic process and
thereby in dementia too (DeLegge & Smoke, 2008). Conversely, long-term use of
non-steroidal anti-inflammatory drugs was associated with a reduced risk of
Alzheimer’s  disease  (Qiu  et  al.,  2007).  Herpes  simplex  virus  –  type1  (HSV-1)
infection contributes to increased proteolysis of APP (Wozniak, Itzhaki, Shipley, &
Dobson, 2007). A number of studies suggest that the presence of HSV-1 in the brain
is considered to be a risk factor for Alzheimer’s disease in elderly APOE ε4 allele
carriers (Itzhaki & Wozniak, 2006).
When oestrogens are administrated in late life may increase the risk of dementia, but
when they are used in midlife, they may have protective effect (Whitmer,
Quesenberry, Zhou, & Yaffe, 2011).  Head trauma has been suggested as a possible
risk factor for Alzheimer’s disease, but this association still remains controversial.
Findings show a relevance to the severity of the injury and the disease i.e. there is a
4.5 fold increased risk for severe injuries (Plassman et al., 2000). Contrary, other
findings show that a head injury may increase the risk of Alzheimer’s disease only in
APOE ε4 allele carriers (Mayeux et al., 1995).
Exposures to heavy metals, such as aluminium, have been found to be a risk factor for
Alzheimer’s disease. Thus, consumption of aluminium from drinking water may be
another risk factor for the disease, whereas silica intake from drinking water may be a
protective factor (Rondeau, Jacqmin-Gadda, Commenges, Helmer, & Dartigues,
2009). Also, occupational exposures to extremely low - frequency electromagnetic
fields (ELF-EMF) has been related to an increased risk of dementia and Alzheimer’s
disease in a numerous studies (Garcia, Sisternas, & Hoyos, 2008).
Sleep-disordered breathing, characterized by recurrent arousals from sleep and
intermittent hypoxemia, and disruption in sleep patterns are linked to poor cognition
and dementia when they occur among older adults, especially in those at greater risk
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such as patients with mild cognitive impairment or other neurodegenerative diseases
(Bombois, Derambure, Pasquier, & Monaca, 2010; Yaffe et al., 2011).
4.6.6 Protective factors
There is scientific evidence that a number of factors may postpone the onset or
prevent the occurrence of Alzheimer’s disease. An active lifestyle operates as a
protective factor for dementia by delaying the clinical onset of the disease, even if the
disease almost exists (Paillard-Borg, Fratiglioni, Xu, Winblad, & Wang, 2012).
Antihypertensive treatments influence positively the atherosclerotic process and
improve the cerebral perfusion, thus provide neuroprotective effects (Qiu, Winblad, &
Fratiglioni, 2005). The initiation of treatment in earlier ages (under 75) and longer
duration of the treatment may have beneficial effect too (Haag, Hofman, Koudstaal,
Breteler, & Stricker, 2009).
Strong adherence to any diet with high intake of fish, fruits and vegetables, and hence,
sufficient quantities of anti-oxidants and polyunsaturated fatty acids may decrease the
risk of Alzheimer’s disease (Kalmijn et al., 1997; Scarmeas et al., 2006) . Similarly,
sufficient  intake  of  vitamins  C,  E,  B6,  B12,  and  folate  may  reduce  the  risk  of  the
disease (Luchsinger & Mayeux, 2004; Morris et al., 2002). Physical exercise may be
either a retarding or even a protective factor for the occurrence of Alzheimer’s disease
(de Bruijn et al., 2013), as it is promoting brain plasticity and affecting positively
cognitive functions maintenance (Qiu et al., 2009). Especially for persons with
genetic susceptibility, physical exercise in the middle age may reduce the risk of the
disease (Rovio et al., 2005).
Moreover, the participation in cognitively stimulating activities and various types of
mentally demanding leisure, social and cultural activities - such as reading, knitting,
gardening, dancing, playing board games and musical instruments, may have
protective effect especially in women (Crowe, Andel, Pedersen, Johansson, & Gatz,
2003; Wilson et al., 2002). Likewise, greater mental activity and work complexity
with people and data during the working life is linked to better memory maintenance
(Valenzuela, Sachdev, Wen, Chen, & Brodaty, 2008).
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4.7 Pharmacologic management of Alzheimer’s disease
The large number of the patients globally and the continuous increasing number of
new cases in both developed and developing countries which is strictly connected to
the rise of longevity, has made the management of Alzheimer’s disease an issue of
high priority for the national governments all around the world and urges for the
development of more effective treatments (Reitz et al., 2011).
The current pharmacological research is focused on the development of medicines
that may halt or reverse the progression with the efforts directed to exploration of new
therapeutic approaches based on the role of the several biomarkers related to
Alzheimer’s  disease  such  as  the  abnormal  deposits  of  amyloid  and  tau  proteins  and
the molecular and biological pathways of the disease (Crews & Masliah, 2010).
The drugs that are approved and widely prescribed by physicians during the last
decades are the cholinesterase inhibitors (AChEIs) and the NMDA (N-Methyl-D-
aspartate) receptor antagonists (memantine). Both drug categories increase the amount
of chemicals called neurotransmitters, in the brain, which are important to memory
function and provide symptomatic relief and a temporary deceleration of the
symptoms of cognitive decline for a period, but they don’t show the same positive
effects in all patients (Vernon, Goldberg, Dash, & Muralimohan, 2007).
Even the presence of numerous of adverse events and the inability to have a reversible
effect on the symptoms of the disease, AChEIs and memantine are the most
commonly prescribed drugs for the confrontation of Alzheimer’s disease. Therefore
the current medical practice focused on the optimization of their use, while expecting
for updates from the global research, given that the discovery of a new drug is a long-
term process taking approximately 10-15 years from the moment of discovery until its
approval and launch in the markets.
The idea of combining the two categories of the aforementioned drugs is based on
their complementary action targeted to two different systems that are involved in the
occurrence of Alzheimer’s disease: the cholinergic and glutamatergic systems.
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The cholinergic hypothesis
The cholinergic hypothesis for Alzheimer’s disease supports that the cognitive
deterioration, which occurs gradually with the disease’s development, is partly
associated with progressive loss of cholinergic neurons and decreasing acetylcholine
(ACh) levels in the brain (Farlow & Cummings, 2007; Francis et al., 1999).
The cholinergic hypothesis of Alzheimer’s disease was based on the presynaptic
deficits  found in the brains of patients with Alzheimer’s disease and tried to explain
the role of ACh in human behaviour deterioration when the disease had occurred. The
cholinergic dysfunction was not associated directly with the cognitive impairment, but
rather indirectly, by inferring with attentional processing (Francis, Palmer, Snape &
Wilcock, 1999).
Although initially the cholinergic research was focused on inhibition of
acetylcholinesterase (AChE), later was reported that butyrylcholinesterase (BuChE)
also plays an important role in the degradation of ACh in normal and Alzheimer’s
patients brains, constituting both AChE and BuChE inhibition an important rational
therapeutic goal in the treatment of the disease (Mesulam, Guillozet, Shaw, & Quinn,
2002).
The glutamatergic hypothesis
Glutamate is the most widely distributed excitatory amino acid neurotransmitter in the
brain under normal conditions. Among other functions, it plays an important role in
the regulation of the NMDA receptor function (Danysz & Parsons, 2003).
There is increasing evidence of the involvement of glutamate-mediated neurotoxicity
in the pathogenesis of Alzheimer’s disease. The glutamatergic hypothesis for
Alzheimer’s disease states that pathogenesis of the disease is related to an
overactivation of NMDA receptors, which is causing excitotoxicity and
neurodegeneration and finally cells death. These are the underlying causes for the
Alzheimer’s patients’ learning and memory deficits that occur during the development
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of the disease (Danysz & Parsons, 2003). Thus, achieving the optimal balance of
glutamate stimulation without excitotoxicity seems to be an important goal for
achieving the optimal treatment of patients with Alzheimer’s disease (Geerts &
Grossberg, 2006). Memantine was developed to response to this need, as it is an
uncompetitive NMDA receptor antagonists that may improve the learning and
memory  of  patients  with  Alzheimer’s  disease  (Danysz  &  Parsons,  2003;  Geerts  &
Grossberg, 2006) .
4.7.1 Memantine
Memantine was found in 1968 and it is the first in a novel class of Alzheimer’s drugs
which act on the glutamatergic system by blocking NMDA glutamate receptors. It is
marketed under the brands Axura and Akatinol by Merz, Namenda by Forest, Ebixa
and Abixa by Lundbeck (Alzheimer's Disease Management Council [ADMC], 2004).
The starting dose for memantine is recommended to be 5 mg once daily increasing by
5 mg increments up to 20 mg/day (10 mg twice daily) (ADMC, 2004).
Memantine has recently received a limited recommendation by the UK's National
Institute for Health and Clinical Excellence (NICE), as it is advised to be used as an
option for managing Alzheimer’s disease for patients in moderate stage who are
intolerant  or  have  a  contraindication  to  AChEI’s,  or  for  patients  in  severe  stage
(National Institute for Health and Clinical Excellence [NICE], 2011). In Australia, the
Pharmaceutical Benefits Advisory Committee (PBAC) has not approved the drug as
non-cost-effective. Thus, Namenda is not available in Australia (Vernon et al., 2007).
Three clinical studies (Reisberg et al., 2003; Tariot et al., 2004; Winblad & Poritis,
1999), on the efficacy of memantine showed that the drug is effective over a range of
outcome measures in patients with moderate-to-severe Alzheimer’s disease. A 4-
months observational study in moderate-to-severe patients states that memantine had
beneficial effects on cognition, activities of daily living and global function in
comparison to pre-treatment state of the patients and independently from their pre-
treatment status (Rainer et al., 2011).
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In the Cochrane systematic review for memantine, which included double-blind,
parallel group, placebo-controlled, randomized trials of the drug in a dose of 20
mg/day compared to placebo, in patients with moderate-to-severe Alzheimer’s,
showed small beneficial effect in two out of three 28 weeks clinical trials .The same
data when pooled, showed a beneficial effect in six months on cognition, daily life
activities and behaviour – especially less agitation symptoms, which are common in
late Alzheimer’s disease stage (McShane, Areosa Sastre, & Minakaran, 2006).
In  the  same  review  the  pooled  data  from  three  unpublished  studies  for  mild-to-
moderate Alzheimer’s disease patients showed marginal beneficial effect at 28 weeks
on cognition which was rather intangible clinically and no effect on behaviour, and
activities of daily living. The drug was found to be well tolerated and the incidence of
adverse effects was low. The authors concluded that the data justified the prescription
of memantine to patients with moderate-to-severe Alzheimer’s and they opposed the
NICE’s committee opinion that the evidence for the clinical effectiveness of
memantine is currently insufficient (McShane et al., 2006).
In contrast, Hermann et al. 2011, stated that memantine has modest benefits in
cognition, function, global and behavioral measures and has presented little potential
for drug-to-drug interactions, thus the authors suggested its use as a therapeutic option
for the treatment of moderate-to-severe Alzheimer’s as a monotherapy or in
combination therapy with an AChEI (Herrmann, Li, & Lanctot, 2011).
4.7.2 AChEIs
There is evidence that the AChEIs (donepezil, rivastigmine and galantamine) have
shown consistent efficacy on cognitive function, functional impairment, and cognitive
stimulation across the spectrum of mild-to-moderate Alzheimer’s disease, and showed
improvement in non-cognitive features of the disease such as neuropsychiatric
symptoms, and caregiver burden (Alzheimer’s Disease International, 2011).
The first step toward the best possible long-term management of Alzheimer’s disease
is the early diagnosis. Furthermore, the early initiation of a treatment with AChEIs
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may stabilize or even reduce the rate of symptomatic cognitive and functional decline
(Farlow & Cummings, 2007; Rountree et al., 2009). The way each AChEI acts is
slightly differentiated. When using donepezil, selective inhibition of AChE occurs,
whereas rivastigmine inhibits both AChE and BuChE, and galantamine inhibits
selectively AChE and simultaneously modulates nicotinic AChR (ACh receptors)
(Farlow & Cummings, 2007).
The best choice among the three AChEIs for an Alzheimer’s patient is highly
individual and mostly depended on adverse events derived from their use
(Alzheimer’s Association, 2012). The applicable dosages of the AChEI’s vary.
Patients are suggested to start with a lower dose increasing gradually, in order to reach
maximum effectiveness. However, a number of patients cannot take the highest dose
due to the adverse events of the drug (Lakey et al., 2012).
NICE recommends using donepezil, rivastigmine and galantamine in people with
mild-to-moderate Alzheimer’s disease (NICE, 2011). Similarly, the US Food and
Drug Administration (FDA) has approved the use of each of the three AChEIs for the
different stage of Alzheimer’s disease. Donepezil may be prescribed for patients in
mild-to-severe stage, whereas galantamine and rivastigmine may be prescribed only
for patients in mild-to-moderate stage (Lakey et al., 2012). Recent studies conducted
with the support of Alzheimer's Society showed that patients in the more severe stage
of Alzheimer’s disease benefit more from AChEIs in motivation, daily function,
cognition, but not in agitation or aggression, and additionally in some cases those
benefits lasted only 6-12 months (Alzheimer’s Association, 2012). Lastly, in a clinical
trial when donepezil was compared to rivastigmine in patients with moderate-to-
severe Alzheimer’s disease, it showed no significant difference between the two
treatments, but donepezil was considered more favourable because the patients on the
donepezil treatment arm suffered less adverse events than the patients on the
rivastigmine  treatment  arm  (Bullock  et  al.,  2005).  Similarly,  in  a  pilot  study  which
compared the sleep of patients with mild-to-moderate Alzheimer’s disease who were
on galantamine and donepezil therapy, the findings were slightly in favour of
galantamine, although both drugs did not affect negatively the sleep of patients
(Ancoli-Israel, Amatniek, Ascher, Sadik, & Ramaswamy, 2005).
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4.7.2.1. Donepezil
Donepezil is a reversible, specific, AChE inhibitor (NICE, 2006 [amended 2009]). It
is marketed under the brands Aricept and Aricept ODT (MedicineNet.com, 2013).
The oral therapy with donepezil should initiate with a dose of 5 mg/day once daily,
and after 4-6 weeks, a dose of 10 mg/day (maximum dose) can be continued if it is
tolerated. In general, the minimum therapeutic dose for donepezil is 5 mg/day
(ADMC, 2004).
A 2 years clinical study showed that donepezil provided small improvements in
cognition and activities of daily living in patients with mild-to-moderate Alzheimer’s
disease  and  was  well  tolerated  (Courtney  et  al.,  2004).  Another  clinical  study
supported that donepezil demonstrated not only a significant improvement in the
symptoms of patients with moderate-to-severe Alzheimer’s disease, but also these
beneficial effects were associated with less caregiving time and lower levels of
caregiver  stress  (Feldman  et  al.,  2003).  Furthermore,  in  a  post-hoc  analysis  of  a
double-blind randomized clinical trial of 24 weeks for moderate-to-severe
Alzheimer’s disease patients, donepezil demonstrated significant efficacy, especially
in the subgroup of patients in the more severe stage of the disease and it was found to
be safe and well-tolerated (Feldman et al., 2005). Further, in an open label study
donepezil showed significant reduction in delusions, irritability and disinhibition in
hospitalized patients for a period of 24 weeks (Barak, Bodner, Zemishlani, Mirecki, &
Aizenberg, 2001).
In a Cochrane review on donepezil, the meta-analysis showed that donepezil
improved cognition significantly regardless of dosage and disease stage. Many
adverse events were recorded, but very few patients left a trial as a direct result of the
intervention. There was also some dose dependent improvement in global clinical
state. Benefits of treatment were also seen in measures of activities of daily living and
behaviour, but no effect on the quality of life. The results were similar for all stages of
Alzheimer’s disease. (Birks & Richard, 2006; (Birks & Richard, 2006; Birks, Grimley
Evans, Iakovidou, Tsolaki, & Holt, 2009).
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4.7.2.2  Rivastigmine
Rivastigmine is an AChE and BuChE inhibitor, which works by increasing the
concentration of acetylcholine at sites of neurotransmission (NICE, 2006 [amended
2009]). It is marketed under the brand Exelon (Alzheimer’s Association, 2012).
The recommended oral therapy starts twice daily at 3 mg/day, with increasing
gradually up to 6 mg/day, 9 mg/day, and 12 mg/day at maximum, with each dose
increase starting after 4 weeks of well-tolerated therapy at each previous stage
(ADMC, 2004). The rivastigmine transdermal patch (9.5 mg⁄ 24 h) has shown similar
efficacy to the rivastigmine capsule (12 mg⁄ day), but with one-third of the incidence
of gastrointestinal side effects (Winblad et al., 2007).
With regard to rivastigmine formulation, in a post hoc analysis of three trials, it was
found that the rivastigmine transdermal patch was better tolerated than rivastigmine
capsules in patients that switched from donepezil tablets and had less gastrointestinal
adverse events (Sadowsky, Farlow, Meng, & Olin, 2010). The results of the a cohort
study, which investigated the prevalence of attention deficits, anxiety, apathy and
agitation symptoms in both community-dwelling and institutionalized Alzheimer’s
patients, showed that the rivastigmine treated patients experienced improvement in
these symptoms together with improvements in caregiver’s burden, with the best
efficacy marked among the patients in mild-to moderate stage. The authors argue that
the effectiveness of rivastigmine may be attributed to its action mechanism, which is
different from the other AChEIs, due to BuChE inhibition which may be more
important as the disease progresses (Gauthier, Juby, Rehel, & Schecter, 2007).
Another analysis of three large clinical trials on premature discontinuation in
rivastigmine-treated patients showed that rivastigmine treated patients had less
deterioration in cognitive function than the patients in the placebo therapy after the
withdrawal  (Farlow,  Potkin,  Koumaras,  Veach,  &  Mirski,  2003).  This  explains  that
the deceleration of cognition worsening in those patients might suggest an effect on
disease progression (Farlow et al., 2003).
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In a Cochrane review on rivastigmine, the meta-analysis showed that high-dose
rivastigmine  (6  to  12  mg  daily)  had  statistically  significant  effect  in  patients  with
mild-to-moderate Alzheimer’s disease in terms of cognition. Significant benefits were
also found in the activities of daily living.
At lower doses (4 mg daily or lower) rivastigmine treatments showed differences in
the same direction, but those differences were statistically significant only for
cognition. The adverse effects which may be attributed to the pharmacokinetics of the
oral drug, were found decreasing either with smaller and more frequent daily doses of
capsules or with the use of the lower dose smaller transdermal patch (J. Birks et al.,
2009).
4.7.2.3 Galantamine
Galantamine is a selective, competitive and reversible inhibitor of AChE and it is
marketed under the brands Razadyne, Razadyne ER, Reminyl (Alzheimer’s
Association, 2012). The oral therapy is recommended to initiate twice daily at 8
mg/day increasing with gradual increments to 16 mg/day and 24 mg/day at maximum
after 4 weeks of well-tolerated therapy in each previous dose regimen. The minimum
therapeutic dose of the drug is 16 mg/day. Especially for the drug Razadyne ER the
administration is different and it is taken once daily in the morning (ADMC, 2004).
Several lines of preclinical evidence indicated that galantamine has cognitive-
enhancing effects (Coyle & Kershaw, 2001). Also in a clinical study which conducted
by  means  of  positron  emission  tomography  (PET  scan),  the  effect  of  galantamine
treatment versus placebo on cortical AChE activity and nicotinic receptor binding in
18 Alzheimer’s patients in mild stage were investigated, and the authors argue that the
patients in galantamine treatment showed better improvement or stabilization of the
disease symptoms compared to those in placebo (Kadir et al., 2008).
Similarly, the results of a 12 weeks clinical trial, investigating the effects of a flexible
dose of galantamine versus placebo in mild-to-moderate Alzheimer’s patients, showed
statistically significant benefits for the galantamine-treated group. The tolerability of
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the drug was good and the adverse effects raised when the dose regimen increased
(Rockwood, Mintzer, Truyen, Wessel, & Wilkinson, 2001).
A secondary analysis of data from a 21-weeks randomized clinical trial (Tariot et al.,
2000) showed that the effect of high-dose galantamine (16-24 mg/day) treatment was
associated with the reduction in behavioural disturbances and the improvement in
existing behavioural problems as well as with significant reduction in caregiver
distress (Cummings, Schneider, Tariot, Kershaw, & Yuan, 2004).
In a Cochrane review on galantamine, the meta-analysis showed that the galantamine
treatment is efficacious and its adverse effects are similar to the other AChEIs (Loy &
Schneider, 2006). Withdrawals due to adverse events increase with increasing in
galantamine dose. The greater proportion of patients had significant improvement or
stabilization in cognitive and global function for at least 6 months and for doses of 16
to 36 mg/day. However, the findings concern mostly the patients in earlier stages of
Alzheimer’s disease (Loy & Schneider, 2006).
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5 Methods
5.1 Search strategy
This study is a systematic review and meta-analysis. We searched PubMed, Embase
and Cochrane library up to September 2012. Articles concerning the efficacy, safety
and tolerability of the combination treatment for Alzheimer’s disease with memantine
and AChEIs were identified up to September 2012. During the process of the first
screening all irrelevant articles and duplications were discarded by each author
separately.  We updated our search later until December 2013.
The databases were searched for the terms “cholinesterase inhibitor” OR “donepezil”
OR “rivastigmine” OR “galantamine” AND “Alzheimer” AND “memantine”. Our
search was limited to clinical trials. The references of selected articles were also hand-
searched and selected. Additionally, we searched the clinical trials registries of
Lundbeck, Forest and Merz.
Inclusion criteria were: (i) randomized controlled trials; (ii) results reported in
English; (iii) trials performed on humans; (iv) probable Alzheimer’s disease; (v)
comparing the effects of treatment with a combination of an AChEI with memantine
(experimental group) with a AChEI (control group). Studies that included other
dementia patients together with Alzheimer’s patients were excluded from the review.
5.2 Outcomes
The outcomes were (1) changes in measures of cognitive function, (2) activities of
daily living function, (3) clinical global function, and (4) behavioural changes.
Moreover, the incidence of adverse events for the intervention and control group was
studied. We defined adverse effects as all unwanted, troublesome or harmful effects
resulted by the therapy.
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5.3 Quality assessment
The quality of the included studies was assessed using the Jadad scale (Higgins &
Green, 2009 [updated March 2011]). We assessed three domains; randomization,
blinding, and patients attrition (the number of patients excluded or lost to follow-up).
5.4 Data extraction
The extracted data were demographic characteristics, the stage of the disease at
baseline, and the treatments used for the intervention and control group. The efficacy
was assessed on the basis of the changes in patients’ outcome measures from their
baseline performance and the safety and tolerability were assessed on the basis of the
quantitative information related to the occurrence of adverse events. For dichotomous
variables, for example the adverse effects, the number of patients experiencing a
particular outcome was determined.
5.5 Meta-analysis
Quality of included trials was assessed using the Jadad Scale (Higgins & Green, 2009
[updated March 2011]). Statistical analysis was performed using a random-effects
meta-analysis (Borenstein, Hedges, Higgins & Rothstein, 2009). Heterogeneity across
studies was assessed by I2 statistic (Higgins & Thompson, 2002). The I-squared
statistic shows the total variation across studies, which is not due to chance. I-squared
statistic less than 25% indicates small inconsistency and more than 50% indicates
large inconsistency (Higgins & Thompson, 2002). Subgroup analyses were performed
for double-blinded and open label trials. Publication bias was assessed by funnel plot
and Egger’s test (Higgins & Green, 2009 [updated March 2011]). Statistical
significance for publication bias was based on a P value  <0.10  (Borenstein  et  al.,
2009).
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6 Results
6.1 Search strategy and selection of studies
Initially, 199 articles were identified in August 2012 and their titles and abstracts were
scrutinized. The research strategy yielded 22 relevant studies (Figure 1). Four open-
label clinical trials (Dantoine et al., 2006; Olin et al., 2010; Riepe et al., 2007; Shua-
Haim et al., 2008) which had only one treatment arm were excluded from meta-
analysis. Moreover, three studies published in local languages and eight duplicates
were excluded from the review.
Figure 1: Flow chart of the search strategy and selection of studies
17 relevant studies
identified and screened
5 double-blinded RCTs and 2
open label RCTs were included
in meta-analysis
199 citations were identified by
electronic searches
182 excluded on first pass based
on abstracts
5 found by
search from
reference lists
15 were excluded
  3 studies in other than
  English language
4 not having two
treatment arms
  8 duplicates
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6.2 Characteristics of included studies
Finally, five double-blinded randomized controlled trials (RCTs) and two open-label
RCTs were included in the meta-analysis (Table 2). Of seven included trials, five
were double-blinded RCTs: (Grossberg et al., 2013; Howard et al., 2012; Lundbeck,
2010; Porsteinsson et al., 2008; Tariot et al., 2004) and two were open-label RCTs:
(Choi et al., 2011; Farlow et al., 2010),
Of the five double-blinded RTCs, three trials studied patients with moderate-to-severe
Alzheimer’s disease, one trial studied patients with moderate and one studied patients
with mild-to-moderate disease (Table 2). Moreover, two open-label RCTs included
patients in mild-to-moderate stage of Alzheimer’s disease.
The quality of the included studies was assessed using Jadad scale (Table 2). All five
double-blinded RTCs were good quality trials and two open-label RCTs were low
quality trials.
Specific characteristics of the seven studies included in the meta-analysis were
presented in Table 3. Two double-blinded RCTs (Grossberg et al., 2013; Porsteinsson
et al., 2008), have administered treatments with any of the three AChEIs, whereas two
other double-blinded RCTs (Howard et al., 2012; Tariot et al., 2004) administered
only donepezil in oral formula. Lastly, one double-blinded RCT (Lundbeck, 2010)
made no reference to the AChEIs treatment. Furthermore, the two open-label RCTs
performed treatments only rivastigmine in transdermal patch formula.
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Table 2: Quality assessment of included studies using the Jadad scale
First author &
year of
publication
Disease
severity
Main results Bias assessment using Jadad scale
Randomization Blinding Attrition
Total
score
Double-blinded RTCs
Tariot., 2004 Moderate-to-
severe
Statistically significant
difference in favour of
combination therapy for
cognition and function
Appropriate/2 Appropriate/2 Reported/1 5
Posteinsson,
2008
Mild-to-
moderate
No statistically significant
difference between groups
Appropriate/2 Appropriate/2 Reported/1 5
Lundbeck, 2010 Moderate The primary analysis
showed no statistically
significant differences
between the memantine and
placebo groups in total brain
atrophy rates (as assessed
using BBSI).
Method of
randomization not
reported/1
Blinding of patients
or caregiver not
reported/1
Reported/1 3
Howard, 2012 Moderate-to-
severe
No statistically significant
difference in favour of the
combined therapy than
single drug therapy either
with donepezil or
memantine.
Appropriate/2 Appropriate/2 Reported/1 5
Grossberg, 2013 Moderate-to-
severe
Statistically significant
difference  in favour of
combination therapy patients
than the single drug therapy
with an AChEI
Appropriate/2 Appropriate/2 Reported/1 5
Open-label RCTs
Farlow, 2010 Mild-to-
moderate
No signifficant difference in
tolerability, cognition,
global function in favour of
the combination therapy.
Method of
randomization not
reported/1
No blinding/0 Reported/1 2
Choi, 2011 Mild-to-
moderate
The combination therapy
was safe and well-tolerated.
No significant difference in
cognition, global function
and behaviour in favour of
the combination therapy.
Method of
randomization not
reported/1
No blinding/0 Reported/1 2
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Table 3: Characteristics of included studies
Authors & year
of publication
Treatment
arm
Sample
size n
Age, mean
(SD),
years
Females,
%
Race
white,
%
Duration of
intervention
(in weeks)
Completion
rate, %
Stable dosing regimen
of AChEI mg (SD)
Dose of
memantine during
the intervention
mg (SD) - dosing
scheme
Double-blinded RCTs
Tariot 2004
Placebo 201 75.5 (8.7) 67 92.5
24
74.6 Donepezil 9.49 (1.88) 5mg/day up-
titrated weekly to
20mg - twice/day
Memantine   203 75.5 (8.4) 63 90 85.1 Donepezil 9.25 (1.79)
Porsteinsson
2008
Placebo 216 76.0 (8.4) 50.5 95
24
88.4
Donepezil 8.9 (2.1),
Rivastgmine 10.0
(2.6), Galantamine
19.4 (5.2)
5mg/day up-
titrated weekly to
20mg - twice/day
Memantine 217 74.9 (7.6) 53.9 92 89.4
Donepezil 9.5 (1.5),
Rivastgmine 9.2 (2.8),
Galantamine 19.7
(4.6)
Lundbeck
2010
Placebo 144
74
52
100 52
77.4 NR
 20mg - twice/day
(weekly titration
not mentioned)
Memantine 134 62 79.2 NR
Howard 2012
Continue
donepezil &
Placebo
memantine 76 77.2 (7.5) 70 95 74 Donepezil 10 mg/day
5mg/day up-
titrated weekly to
20mg - twice/day
Continue
donepezil &
active
memantine 73 77.5 (9.0) 67 92 52 79.5 Donepezil 10 mg/day
Grossberg
2013
Placebo 335 76.8 (7.8) 72.5 93
24
81.2
Donepezil 7.8 (2.6),
Rivastgmine 6.8 (2.9),
Galantamine 13.5
(5.4)
7mg/day, up-
titrated weekly to
28mg/day -
once/day - mean
17.00Memantine
ER* 342 76.2 (8.4) 71.6 95 79.8
Donepezil 8.0 (2.8),
Rivastgmine 6.8 (2.6),
Galantamine 13.5
(5.7)
Open-label RCTs
Farlow 2010
FF*
Rivastigmine
patch 126 77.3 (7.92) 58.7 84.1 25 75.4
Rivastigmine
transdermal patch
4.6mg/day
Not reported
Rivastigmine*
plus
memantine 135 77.2 (8.18) 57 91.1 25 75
Rivastigmine
transdermal patch
4.6mg/day
Choi 2011
Rivastigmine
patch 84 74.7 (7.7) 83.3 0 16 83.3
Rivastigmine 10cm3
patch/day
20mg/dayRivastigmine*
plus
memantine 88 75.0 (7.3) 75 0 16 87.5
Rivastigmine 10cm3
patch/day
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6.3 Outcome assessment tools
The performed efficacy measure scales were different among the trials. Certain
measure scales were primary efficacy tools for some trials, whereas they were
secondary efficacy tools for some other trials. Especially, in the included open-label
RCTs the efficacy assessment was a secondary outcome measure, while primary aim
of these trials were safety and tolerability control.
The outcomes of the studies were assessed using the following assessment tools; the
Mini  Mental  State  Exam  (MMSE)  (Folstein,  Folstein,  &  McHugh,  1975),  the
Clinician’s Interview-Based Impression of Change plus caregiver’s input (CIBIC-
plus) (Schneider et al., 1997), the Severe Impairment Battery (SIB) (Panisset,
Roudier, Saxton, & Boller, 1994), the Alzheimer’s Disease Cooperative Study
Activities of Daily Living (ADCS-ADL) scale (19- and 23-item) (Galasko et al.,
1997), the Bristol Activities of daily Living Scale (BADLS) (Bucks, Ashworth,
Wilcock & Siegfried, 1996) and the Neuropsychiatric Inventory (NPI) (Cummings et
al., 1994).  Especially, when patients in more severe stage were included in the trial,
the 19 items version of the ADCS-ADL scale (Galasko et al., 1997) was used, while
for patients in milder stage the 23 items version was used (Table 4).
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Table 4: Common assessment tools used in the evaluation of pharmacotherapy for
Alzheimer’s disease
Scale Domain Score Range Indication of the
higher score
Interviewee
Low       High
Mini-Mental State Exam
(MMSE) (Folstein et al.,
1975)
Cognition 0 30 Better cognition Patient
Severe Impairment Battery
(SIB) (Panisset et al., 1994)
Cognition 0 100 Better cognition Patient
Alzheimer’s Disease
Cooperative Study—
Activities of
Daily Living (ADCS-ADL)
(Galasko et al., 1997)
Function/activities
of daily living
0 78 Better ADL
performance
Caregiver
Clinician's Interview-Based
Impression of Change Plus
Caregiver Input (CIBIC-
Plus) (Schneider et al.,
1997)
Global change 1 7 Global worsening Patient,
Caregiver
Neuropsychiatric Inventory
(NPI) (Cummings et al.,
1994)
Neuropsychiatric
symptoms –
behavioral change
0 144 Greater disturbance Caregiver
Bristol Activities of Daily
Living Scale (BADLS)
(Bucks et al., 1996)
Function 0 60 Poorer functioning Patient
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6.4 Cognitive function outcome
Six studies were included in the meta-analysis of cognitive function: four double-
blinded  RCTs  and  two  open-label  RCTs  (Figure  2).  The  heterogeneity  across  the
studies was high (I2 = 98%). Among the double-blinded RCTs one study assessed the
cognitive function using MMSE (Folstein et al., 1975), another using the standardized
MMSE (Molloy & Standish, 1997) and two other studies using SIB (Panisset et al.,
1994). In the two open-label RCTs the cognitive function was assessed using MMSE
(Folstein et al., 1975), but the study conducted on Korean population (Choi et al.,
2011) used the Korean version of the scale (Kim et al., 2010). The pooled estimate of
six trials showed modest beneficial effect for the combination therapy over the
monotherapy (Raw mean difference 0.96, 95% CI -0.87 to 2.79). The estimate was
not, however, statistically significant.
Interestingly, the two double-blinded RCTs which included moderate-to-severe
patients  and  used  the  SIB scale  (Panisset  et  al.,  1994)  (the  most  appropriate  for  the
cognitive assessment of moderate-to-severe patients) showed significant effects for
the combination therapy compared to the monotherapy (Raw mean difference 3.28,
95% CI 2.64-3.92), whereas the studies that included mild-to moderate patients
showed no benefit for the combination therapy group over the monotherapy group.
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Figure 2. A meta-analysis of six trials on cognitive outcome (mean difference) in the
intervention group compared with the control group.
Overall (I2 = 98.0%, p = 0.000)
Randomized, open label, controlled clinical trial-MMSE
Subtotal (I2 = 23.4%, p = 0.253)
Subtotal (I-squared = .%, p = .)
Tariot 2004
Porsteinsson 2008
Farlow 2010
Subtotal (I2 = 0.0%, p = 0.439)
Choi 2011
Howard 2012
Grossberg 2013
Randomized, double blinded, controlled clinical trial-MMSEd
Randomized, double blinded, controlled clinical trial-MMSE
First author and year of publication
Subtotal (I2 = .%, p = .)
Randomized, double blinded, controlled clinical trial-SIB
0.96 (-0.87, 2.79)
3.28 (2.64, 3.92)
0.80 (-0.05, 1.65)
3.40 (3.27, 3.53)
0.50 (-0.10, 1.10)
-0.90 (-1.84, 0.04)
-0.63 (-1.26, 0.00)
-0.40 (-1.25, 0.45)
0.80 (-0.10, 1.60)
2.40 (0.69, 4.11)
ES (95% CI)
0.50 (-0.10, 1.10)
100.00
32.57
16.81
17.43
17.13
16.69
33.50
16.81
16.81
15.13
Weight
17.13
, %
0-4 -2 -1 1 2 4
Mean difference
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6.5 Activities of daily living outcome
Six studies were included in the meta-analysis of cognitive function: four double-
blinded  RCTs  and  two  open-label  RCTs  (Figure  3).  The  heterogeneity  across  the
studies was found to be high (I2 = 81.9%). Five of the studies assessed the activities of
daily living outcome using ADCS-ADL measure scale (Galasko et al., 1997), while
one double-blinded RCT with moderate-to-severe patients used BADLS (Bucks et al.,
1996). The ADCS-ADL (Galasko et al., 1997) scale of 19 items was used in two
studies with moderate-to-severe patients. The double-blinded RCT with mild-to-
moderate patients used the version of 23 items and the two open-label RCTs did not
clarify the version of the measurement scale.
The pooled estimate of six trials showed no difference between the combination
therapy and the monotherapy (Raw mean difference 0.04, 95% CI -1.12 to 1.20).  A
meta-analysis of three double-blinded RCTs with a range of mild-to-severe patients
showed modest non-significant beneficial effect for the combination therapy
compared with the monotherapy (Raw mean difference 0.81, 95% CI -0.13 to 1.74).
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Figure 3. A meta-analysis of six trials on the activities of daily living outcome in the
intervention group compared with the control group.
Overall (I2 = 81.9%, P = 0.000)
Subtotal (I2 = 69.8%, P = 0.036)
Randomized, double blinded, controlled clinical trial-ADCS-ADL
Subtotal (I2 = 84.2%, P = 0.012)
Choi 2011
Randomized, double blinded, controlled clinical trial-BADLS
Farlow 2010
Randomized, open label, controlled clinical trial-ADCS-ADL
Subtotal (I2 = .%, P= .)
Grossberg 2013
Tariot 2004
Howard 2012
Porsteinsson 2008
0.04 (-1.12, 1.20)
0.81 (-0.13, 1.74)
-1.18 (-5.39, 3.04)
ES (95% CI)
1.00 (-1.46, 3.46)
-3.30 (-5.57, -1.03)
-0.50 (-2.20, 1.20)
0.60 (-0.50, 1.70)
1.40 (1.30, 1.50)
-0.50 (-2.20, 1.20)
-0.20 (-1.60, 1.30)
100.00
60.37
23.92
Weight
11.51
12.41
15.70
19.50
23.59
15.70
17.28
, %
0-4 -2 -1 1 2 4
Mean difference
First author and year of publication
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6.6 Behavioural outcome
Five studies were included in the meta-analysis of behavioural change: four double-
blinded RCTs and one open-label RCT (Figure 4). The studies were heterogeneous (I2
= 80.2%). All the double-blinded RCTs estimated the behavioural outcome using NPI
(Cummings et al., 1994), whereas the open-label RCT used the caregivers assessed
scale  CGA-NPI  (Kang  et  al.,  2004).  The  pooled  estimate  of  five  trials  showed
significant superiority of the combination therapy over the monotherapy (Raw mean
difference -2.22, 95% CI -4.27 to -0.17). Only patients with moderate-to-severe stage
benefited from the combination therapy, but not those with mild-to-moderate stage.
Figure 4. A meta-analysis of five trials on the activities of behavioural outcome in the
intervention group compared with the control group
Overall (I2 = 80.2%, P= 0.000)
Subtotal (I2 = 81.9%, P = 0.001)
Porsteinsson 2008
Choi 2011
Tariot 2004
Grossberg 2013
First author and year of publication
Subtotal (I2 = .%, P = .)
Randomized, open label, controlled clinical trial-CGA-NPI
Randomized, double blinded, controlled clinical trial-NPI
Howard 2012
-2.22 (-4.27, -0.17)
ES (95% CI)
-2.60 (-4.74, -0.45)
0.30 (-1.70, 2.40)
0.20 (-3.86, 4.26)
-3.80 (-3.99, -3.61)
-2.70 (-4.76, -0.64)
0.20 (-3.86, 4.26)
-5.10 (-9.80, -0.30)
100.00
Weight
86.35
22.78
13.65
29.44
22.73
13.65
11.40
, %
0-4 -2 -1 1 2 4
Mean difference
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6.7 Global function outcome
Three double-blinded randomized control studies on global function were included in
the meta-analysis (Figure 5). All three studies assessed the global function using
CIBIC-Plus measure scale (Schneider et al., 1997), which is an end-point assessment
tool applied by caregivers. The pooled estimate of three trials showed small benefit in
the global function for the combination therapy compared with the monotherapy (Raw
mean difference -0.21, 95% CI -0.33 to -0.09).
The three double-blinded RCTs covered a range of mild-to-severe patients.
Interestingly, the two trials that included moderate-to-severe patients showed
significant small improvement in the global function for patients on the combination
therapy, while the study conducted in patients with mild-to-moderate stage showed no
significant benefit.
Figure 5. A meta-analysis of three trials on global function
Overall (I2 = 61.9%, P = 0.073)
First author and year of publication
Grossberg 2013
Porsteinsson 2008
Tariot 2004
-0.21 (-0.33, -0.09)
WMD (95% CI)
-0.30 (-0.48, -0.12)
-0.04 (-0.22, 0.14)
-0.25 (-0.26, -0.24)
100.00
Weight
24.06
23.51
52.43
, %
0-1 1
Mean difference
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6.8 Adverts events outcome
All five double-blinded RCTs and two open-label RCTs reported adverse effects for
the intervention and control group. The pooled estimate of seven trials showed no
difference between the two groups (Relative risk 1.03, 95% CI 0.96-1.10, I2 = 0.0%)
(Figure 6). The double-blinded RCTs and open-label RCTs showed similar results.
There are common adverse events which are typical for the AChEIs treatments such
as nausea, vomiting, diarrhea, anorexia, insomnia, and fatigue. Memantine has also
common adverse events such as confusion, somnolence, falls, and headache (M. R.
Farlow & Cummings, 2007). The adverse events were the primary reason for
discontinuation of the treatment in the studies.
Figure 6. A meta-analysis of seven trials on any side effect in the intervention group
compared to the control group.
Overall (I2 = 0.0%, P = 0.700)
Randomized, double blinded, controlled clinical trial
Subtotal (I2 = 0.0%, P = 0.528)
Farlow 2010
Choi 2011
Lundbeck 2010
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Subtotal I2 = 0.0%, P = 0.861)
Porsteinsson 2008
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First author and year of publication
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0.87 (0.66, 1.14)
1.08 (0.94, 1.24)
0.90 (0.55, 1.45)
0.98 (0.87, 1.10)
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78.88
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6.9 Publication bias
There was no evidence of publication bias for all outcomes. All seven studies reported
data on adverse effects. The Figure 7 shows a funnel plot for this outcome.
Figure 7: Funnel plot of seven trials on adverse effects
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7 Discussion
7.1 Main findings
This  meta-analysis  of  seven  clinical  trials  showed  that  a  combination  therapy  of  an
AChEI with memantine is associated with modestly better effects in terms of
cognition and global function than a monotherapy with an AChEI. The effects of the
combination therapy were no better than a monotherapy for daily living activity.
However, the combination therapy showed benefits over a monotherapy for the
behavioural outcome and the effect was independent of the stage of the disease.
Although the meta-analysis of double-blinded RCTs and open-label controlled trials
on the effects of the combination therapy on cognition were not statistically
significant.  The two double-blinded RCTs which included patients with moderate-to-
severe Alzheimer’s disease and used the SIB scale (Panisset et al., 1994), which is the
most  appropriate  for  the  cognitive  assessment  of  this  category  of  patients,  showed
significant effects for the combination therapy.
Our subgroup analysis according to the stage of the disease, mild-to-moderate versus
moderate-to-severe, may indicate that the combination therapy is more appropriate
and should be administered to patients in more advanced stages.
Moreover, this meta-analysis showed a similar rate of adverse effects for a
combination therapy and a single therapy.
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7.2 Combination therapy in regard to the stage of Alzheimer’s
disease
The findings of this study do not support the use of combination therapy for the early
stage of Alzheimer’s disease, but show a beneficial effect over a single therapy for
moderate-to-severe stage of the disease.
A number of narrative reviews found that the combination therapy is safe and well
tolerated and they supported the superiority of the combination therapy (Parsons et al.,
2013; Patel & Grossberg, 2011; Tampi & van Dyck, 2007; Xiong & Doraiswamy,
2005). They have recommended the combination therapy as the best current treatment
strategy especially for patients in moderate-to-severe stage of Alzheimer’s disease.  A
Cochrane systematic review on the efficacy of memantine supported memantine as a
monotherapy or in combination with an AChEI for patients with moderate to severe
Alzheimer’s disease (McShane et al., 2006).
For the earlier stages of Alzheimer’s disease, the results on the beneficial effects of
the combination therapy are inconsistent. Some studies found no evidence that the
combination therapy may provide some benefits in that stage of the disease (Xiong &
Doraiswamy, 2005). Some other studies demonstrated modest benefits (Tampi & van
Dyck, 2007) or similar beneficial effect for the early stage of the disease (Patel &
Grossberg, 2011). Moreover, two reviews found that the combination therapy with
memantine showed better functional and neuroprotective benefits for patients in the
moderate stage of Alzheimer’s disease (Farlow & Cummings, 2007; Standridge,
2004) .
However, the opinions expressed by narrative reviews may have been affected by
selection and interpretation bias. The selection of studies depends on the preference
and the criteria of the authors which may be more arbitrary than those set for
systematic reviews.
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A number of cohort studies also support the combination therapy for advanced stage
of Alzheimer’s disease. A study (Schneider, Insel, Weiner, & Alzheimer's Disease
Neuroimaging Initiative, 2011) found no benefits for the combination therapy in
patients with mild Alzheimer’s disease. Moreover, several studies (Atri, Shaughnessy,
Locascio, & Growdon, 2008; Lopez et al., 2009; Seinela, Virtanen, & Ripsaluoma,
2012)  showed beneficial effects for the combination therapy in patients in more
advanced stage. Particularly, the study by Lopez et al. (Lopez et al., 2009) suggested
that the combination therapy may delay nursing admission and showed beneficial
effects on communication skills and physical health of treated patients.
7.3 Medication adherence
The adherence to medication is discussed in a number of the cohort studies. There is
scientific evidence on medication adherence on the impact of the therapy. The longer
patients persist with treatment, the better they perform on cognitive, functional and
global outcomes (Rountree et al., 2009). The importance of adherence to the treatment
in the long-term was supported also by two cohort studies (Atri et al., 2008; Lopez et
al., 2009).
7.4 Dose regimen and drug formulation
The dose regimen may play a role in the effect of a therapy either demonstrating
better efficacy or affecting the side effects. In a combination therapy, a higher daily
dose or an extended release formula of memantine may have better effect (Grossberg
et al., 2013).
Similarly,  the  drug  formulas  may  play  a  role  in  the  effects  of  a  treatment  for
Alzheimer’s disease. However, rivastigmine patches of different dosage had similar
efficacy for groups of Alzheimer’s patients in the same stage (Choi et al., 2011;
Farlow et al.,  2010).  With regard to drug formulation, the authors of a study, which
reported the beneficial effects for the combination therapy, argued that this effect may
be associated with relatively higher concentrations of rivastigmine in capsule formula
(Farlow et al., 2010).
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7.5 Efficacy assessment tools and their effects on the results
The tools for the assessing the treatment efficacy for Alzheimer’s disease have varied
in the clinical trials.  The efficacy assessment tools can have an impact on the results
of the clinical trials.
For example, when trying to determine the disease severity using MMSE (Folstein et
al., 1975), any physical, sensory or learning disabilities, communication difficulties,
or sufficient fluency of the observed patients should be taken into account. They may
affect and bias the results (NICE, 2011). The MMSE (Folstein et al., 1975) scale may
evaluate adequately the mild-to-moderate Alzheimer’s patients’ cognitive status, but
for  more  severe  stages  of  the  disease  the  SIB  scale  (Panisset  et  al.,  1994)  is  more
appropriate tool (NICE, 2011).
In the study by Howard et  al.  (2012),  the SMMSE scale (Molloy & Standish,  1997)
was used to measure the effects of the combination therapy on cognition in moderate-
to-severe Alzheimer’s patients and showed no significant improvement. These
reported values may have been affected by a floor effect which may conceal an
overestimation of the patients’ deterioration and biased efficacy outcome (Schmitt &
Wichems, 2006). In contrast, the effect of the combination treatment on cognition in
moderate-to-severe Alzheimer’s patients, when was assessed by the SIB scale
(Panisset et al., 1994) in the studies by Tariot et al. (Tariot et al., 2004) and Grossberg
et  al.  (Grossberg  et  al.,  2013)  showed  significant  improvement.  Similarly,  in  the
Korean population study (Choi et al., 2011) the Korean specified MMSE scale (Kim
et al., 2010) was applied for the assessment of mild-to-moderate Alzheimer’s patients
with low educational status. This scale has been found relatively insensitive in
detecting the early stage of dementia, leading to a higher false negative rate (Kim et
al., 2010). In this case the insensitivity of the scale and the low educational status may
both have biased the results.
The CIBIC-Plus (Schneider et  al.,  1997) has various formats with different terms of
depths and structure which may influence the outcome’s validity, especially when
estimating outcomes across different studies. Thus it may be an insensitive assessment
tool in detecting patients’ global function (Quinn et al., 2002).
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7.6 Adverse effects of Alzheimer's drugs
The efficacy of a drug depends on its safety and tolerability. Some adverse effects can
lead to lack of compliance in a therapy. In Alzheimer’s disease the patients’
compliance is also affected by a number of comorbidities and concomitant medication
use.
This meta-analysis showed a similar rate of the adverse effects for a combination and
a single therapy. However, the dropouts differed between the studied groups in the
included trials. In two studies (Farlow et al., 2010; Grossberg et al., 2013; Howard et
al., 2012) the dropouts were 1.5-fold more in the combination therapy group than the
monotherapy group. Contrary, in two other studies (Porsteinsson et al., 2008; Tariot et
al., 2004) there were more withdrawals in the monotherapy group than in the
combination therapy group. Moreover, the two open-label studies included in this
review had more drop-outs in the combination therapy group. The differences in the
dropout rates between intervention and control group suggest that a combination
therapy may have more adverse effects than a monotherapy.
7.7 The rate of dropouts and imputation methods for missing
data
Although the meta-analysis showed similar rate of adverse effects between the two
therapies, the occurrence of dropouts differed between the studied groups in different
trials.  The rate of dropouts and the choice of imputation method for handling missing
data may also affect the difference between a combination therapy and a single
therapy.
Intention-to-treat (ITT) approach was the most commonly used method for analysing
data with missing information in the included RCTs. This method may help to avoid
bias associated with the effects of crossover and dropouts. Intention-to-treat method
presupposes that the participants should be analysed in the groups to which they were
randomized, regardless of whether they received or they adhered to the allocated
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intervention. Hence, this principle may lead to consequent concealment of missing
data or adherence to protocol guidelines, biasing the efficacy and safety outcomes at
any direction (Hollis & Campbell, 1999).
The last observation carried forward (LOCF) imputation method was commonly used
for handling missing data in RCTs. In this approach, missing data are replaced with
the last available observation values. This method can produce biased estimates of the
treatment effects (Little et  al.,  2012).  Especially for Alzheimer’s patients,  the use of
the last value before dropout as end point measure may conceal the degenerative
progression of the disease, because it may be more optimistic than if the value was
yielded upon the completion of the treatment. Thus, last observation carried forward
approach of missing data management, may favour the therapy arms with most
dropouts underestimating the decline of patients.
The included trials in this meta-analysis did not provide adequate information for
assessing possible bias introduced by use of the last observation carried forward
method. However, two trials  (Grossberg et al., 2013; Howard et al., 2012) performed
a sensitivity analysis to assess the effects of missing data on the results. The results of
these trials remained robust after a sensitivity analysis.
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8 Future suggestions
The clinical trials included in this meta-analysis were conducted for a relatively short
period, of one year maximum. This meta-analysis showed that a combination therapy
of memantine with an AChEI may provide some benefits in cognitive function, global
function and behavioral symptoms in Alzheimer’s patients in advanced stages
compared to a monotherapy. In addition, three observational studies (not included in
this meta-analysis) reported similar results, supporting the efficiency of a combination
therapy especially for this category of patients.
Further studies with a longer follow-up time are needed. Moreover, future studies
investigating the efficacy of a treatment should account for the degenerative character
of Alzheimer’s disease, the speed of the disease’s progression, a dose-response
relationship, individual characteristics of patients, such as comorbidities (i.e. diabetes,
hypertension), biomarkers (i.e. genes associated to Alzheimer’s disease, cerebrospinal
fluid tau and amyloid protein), other medications and drug interactions, and
environmental factors which may affect the disease’s progress. Moreover, personal
coexisting characteristics of the patients, such as low educational status, learning
problems and communication difficulties should be considered to avoid
misinterpretation when assessing the efficacy of a treatment. Finally, not all patients
may benefit from the combination treatment. Identification of subgroups of patients
with Alzheimer’s disease who will benefit more from the combination treatment is
needed.
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